Home
HelpTest ID RAVUM Ravulizumab Complement Blockage Monitoring, Serum
Advisory Information
To measure therapeutic concentrations of ravulizumab, order RAVU / Ravulizumab, Serum.
Specimen Required
Patient Preparation: Fasting preferred.
Collection Container/Tube: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge at 4° C and aliquot serum into plastic vial.
3. Freeze specimen within 30 minutes.
Useful For
Monitoring of complement blockage by ravulizumab
Investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, dense-deposit disease
Highlights
Ravulizumab is a new complement C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the FcRn immunoglobulin receptor and change the affinity of the molecule for C5.
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Reporting Name
Ravulizumab Complement Blockage, SSpecimen Type
Serum RedSpecimen Minimum Volume
0.2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum Red | Frozen | 14 days |
Reference Values
≥46% normal
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
86161
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| RAVUM | Ravulizumab Complement Blockage, S | 74520-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 609500 | Ravulizumab Complement Blockage, S | 74520-8 |